Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.49 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7747761 | 0.84 | CASP2 (0.59) | CASP2FAAHCA12CA1CA2 | |
| SCHEMBL13853974 | 0.83 | CASP2 (0.57) | CASP2FAAHCA12CA1CA2 | |
| SCHEMBL18248592 | 0.81 | CASP2 (0.56) | CASP2FAAHNAAALPAR3 | |
| SCHEMBL30203244 | 0.81 | PPARD (0.48) | FAAHCA12CA1CA2CA9 | |
| SCHEMBL11523083 | 0.79 | CASP2 (0.60) | CASP2FAAHNAAAEPHX1S1PR2 | |
| SCHEMBL7747785 | 0.79 | EPHX1 (0.61) | CA12CA1CA2CA9EPHX1 | |
| SCHEMBL7747982 | 0.78 | CASP2 (0.47) | CASP2FAAHCA12CA1CA2 | |
| SCHEMBL9575783 | 0.78 | FAAH (0.54) | CASP2FAAHNAAA | |
| SCHEMBL13853970 | 0.78 | FAAH (0.54) | CASP2FAAHNAAA | |
| SCHEMBL11703368 | 0.77 | PPARD (0.47) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10369140-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180133198-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133198-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | DGAT2, MGAT2, MGAT1 | CASP2 3619/4885FAAH 733/4885CA12 4029/4885 |
| US-10369140-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | DGAT2, MGAT2, MGAT1 | CASP2 3619/4885FAAH 733/4885CA12 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.